Primary Graft Dysfunction (PGD) is severe acute lung injury after lung transplantation. PGD has a major impact on outcomes following lung transplantation, markedly increasing morbidity, mortality, and cost. Thus, reduction in the incidence of PGD would dramatically improve clinical and economic outcomes following lung transplantation. In addition, concern about PGD following lung transplantation is the main reason why potential lung donors are not considered suitable for use. Consequently, reduction of PGD incidence could also increase the number of transplants performed. Despite the clear importance of PGD to lung transplantation, fundamental questions about characteristics of donors and recipients that increase PGD risk remain unanswered. Likewise, investigation of biological mediators in PGD risk and pathogenesis is in the early stages, though recent studies by our group have begun to address these questions.
We aim to study the association of clinical variables in donors and recipients with subsequent development of PGD. Specifically, we hypothesize that inherent clinical risk factors of the donor and recipient influence the risk of PGD. This study takes advantage of our established multicenter cohort study infrastructure to identify an expanded sample of patients to achieve the following specific aims: 1) determine the association of clinical and biological risk factor variables in recipients with development of PGD following lung transplantation;2) determine the association of clinical risk factor variables in donors with development of PGD following lung transplantation;and 3) develop and validate a predictive model for PGD based on donor and recipient clinical and biological variables. The goals of our aims are to both provide insight into the mechanisms of PGD by studying clinical risk factors, as well as aid in prediction of PGD based on donor and recipient characteristics. To achieve these aims, we will perform a multicenter cohort study of 1700 patients undergoing lung transplantation at 9 centers in the U.S. Greater understanding of these risk factor variables will lead to improved recipient selection, donor selection, and donor-recipient matching to reduce the incidence of PGD. Identification of clinical and biological risk factors will also suggest further clinical and bench research into understanding mechanisms of these risk factor associations. In addition, better ability to predict PGD will likewise directly influence lung transplant practice, leading to expansion of available donor organs in lower risk candidates, as well as identification of high risk procedures for clinical trial enrollment.
|Tong, Yubing; Udupa, Jayaram K; Torigian, Drew A et al. (2017) Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates. PLoS One 12:e0168932|
|Clarke, Erik L; Sundararaman, Sesh A; Seifert, Stephanie N et al. (2017) swga: a primer design toolkit for selective whole genome amplification. Bioinformatics 33:2071-2077|
|Baldwin, Matthew R; Singer, Jonathan P; Huang, Debbie et al. (2017) Refining Low Physical Activity Measurement Improves Frailty Assessment in Advanced Lung Disease and Survivors of Critical Illness. Ann Am Thorac Soc 14:1270-1279|
|Reilly, John P; Christie, Jason D; Meyer, Nuala J (2017) Fifty Years of Research in ARDS. Genomic Contributions and Opportunities. Am J Respir Crit Care Med 196:1113-1121|
|Borders, Catherine F; Suzuki, Yoshikazu; Lasky, Jared et al. (2017) Massive donor transfusion potentially increases recipient mortality after lung transplantation. J Thorac Cardiovasc Surg 153:1197-1203.e2|
|Diamond, J M; Cantu, E; Porteous, M K et al. (2017) Peripheral Blood Gene Expression Changes Associated With Primary Graft Dysfunction After Lung Transplantation. Am J Transplant 17:1770-1777|
|Diamond, Joshua M; Arcasoy, Selim; McDonnough, Jamiela A et al. (2017) Adipose Gene Expression Profile Changes With Lung Allograft Reperfusion. Am J Transplant 17:239-245|
|Monticelli, Laurel A; Buck, Michael D; Flamar, Anne-Laure et al. (2016) Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nat Immunol 17:656-65|
|Diamond, J M; Shah, R J; Cantu 3rd, E et al. (2016) Survey of Lung Transplant Community's Views on Primary Graft Dysfunction. Am J Transplant 16:724-6|
|Cantu, E; Suzuki, Y; Diamond, J M et al. (2016) Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. Am J Transplant 16:833-40|
Showing the most recent 10 out of 52 publications